According to several clinical trials, baricitinib has shown to improve arthritis symptoms not only in DMARD-naive patients, but also in patients with an inadequate response to MTX, csDMARDs, or TNF inhibitors [142,143,144]. This evidence concerns the gene TNF and Arthritis.